Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients

BACKGROUND: Tacrolimus is a first-line immunosuppressive therapy to prevent rejection and graft failure in kidney transplant recipients. Once-daily extended-release tacrolimus tablets (LCPT) have been shown to be efficacious, particularly for Hispanic and Black patient subpopulations who are rapid m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurwitz, Jason T, Grizzle, Amy J, Tyler, Carmelina S, Zapata, Lorenzo Villa, Malone, Daniel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390924/
https://www.ncbi.nlm.nih.gov/pubmed/34185556
http://dx.doi.org/10.18553/jmcp.2021.27.7.948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390924/
https://www.ncbi.nlm.nih.gov/pubmed/34185556
http://dx.doi.org/10.18553/jmcp.2021.27.7.948

Ejemplares similares